The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation

scientific article published on 01 January 1996

The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1097/00007890-199601270-00015
P698PubMed publication ID8600632

P2093author name stringK Tanaka
N Ozaki
H Egawa
T Hashida
Y Yamaoka
Y Inomata
T Kiuchi
K Satomura
S Uemoto
H Okajima
P433issue2
P407language of work or nameEnglishQ1860
P304page(s)247-252
P577publication date1996-01-01
P1433published inTransplantationQ15730500
P1476titleThe evolution of immunosuppression with FK506 in pediatric living-related liver transplantation
P478volume61

Reverse relations

cites work (P2860)
Q47329951A nomogram for predicting the optimal oral dosage of tacrolimus in liver transplant recipients with small-for-size grafts
Q73932596Advances in the development of immunosuppressive agents in organ transplantation
Q43584355Analysis of alloreactivity and intragraft cytokine profiles in living donor liver transplant recipients with graft acceptance
Q77583304Biliary complications in pediatric living related liver transplantation
Q50114384Biliary reconstruction in right lobe living-donor liver transplantation: Comparison of different techniques in 321 recipients
Q73322566Changes in portal venous pressure in the early phase after living donor liver transplantation: pathogenesis and clinical implications1,2
Q77067731Clinical implications of flow cytometry crossmatch with T or B cells in living donor liver transplantation
Q34332261Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation
Q47223579Correlation between graft size and necessary tacrolimus dose after living-related liver transplantation
Q73278354Effectiveness of 15-deoxyspergualin on steroid-resistant acute rejection in living related liver transplantation
Q44912010Effects of post-transplant enteral nutrition with an immunomodulating diet containing hydrolyzed whey peptide after liver transplantation
Q57106909Etiologies, risk factors, and outcomes of bacterial cholangitis after living donor liver transplantation
Q51503491Exposure of hepatic sinusoidal mononuclear cells to UW solution in situ but not ex vivo induces apoptosis.
Q40552763Forecasting of Blood Tacrolimus Concentrations Based on the Bayesian Method in Adult Patients Receiving Living-Donor Liver Transplantation
Q39001834Impact of Antibodies That React With Liver Tissue and Donor-Specific Anti-HLA Antibodies in Pediatric Idiopathic Posttransplantation Hepatitis
Q91850730Impact of Graft Quality and Fluid Overload on Postoperative Massive Ascites After Living Donor Liver Transplantation
Q43476264Impact of the development of a liver transplant program on the treatment of biliary atresia in an institution in Japan
Q89057724Liver Transplantation for Intermediate-Stage Hepatocellular Carcinoma
Q53807979Liver transplantation for advanced hepatocellular carcinoma in patients with Child-Pugh A and B.
Q37360177Liver transplantation for small hepatocellular carcinoma
Q72991926Living related liver transplantation from heterozygote genetic carriers to children with Wilson's disease
Q35422169Long-term outcomes of hepatic resection versus living donor liver transplantation for hepatocellular carcinoma: a propensity score-matching study
Q46048992Long-term results of pediatric liver transplantation: an analysis of 569 transplants
Q60932740Low Titers of Antidonor ABO Antibodies After ABO-Incompatible Living Donor Liver Transplantation: A Long-Term Follow-Up Study
Q47361181Lower limit of the graft-to-recipient weight ratio can be safely reduced to 0.6% in adult-to-adult living donor liver transplantation in combination with portal pressure control.
Q74219332Lymphoproliferative disorders in patients undergoing living-related liver transplantation
Q77632858Neoral-based immunosuppression in living-related donor liver transplantation
Q38796186New-onset diabetes mellitus after living-donor liver transplantation: association with graft synthetic function.
Q79633266Outcomes of adult-to-adult living donor liver transplantation: a single institution's experience with 335 consecutive cases
Q74579834Pediatric liver transplantation with cadaveric or living related donors: comparative results in 90 elective recipients of primary grafts
Q52230151Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients.
Q36055374Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients
Q74219327Posttransplant hepatitis B infection in liver transplantation with hepatitis B core antibody-positive donors
Q83675820Recurrence of hepatocellular carcinoma after living donor liver transplantation: what is the current optimal approach to prevent recurrence?
Q80335933Remaining caudate lobe in the right lobe graft in living donor liver transplantation: a blind spot?
Q78256916Severe late acute allograft rejection in a child after living-related auxiliary partial orthotopic liver transplantation for ornithine transcarbamylase deficiency
Q40584058Significance of serial real-time PCR monitoring of EBV genome load in living donor liver transplantation
Q43298558Surgical complications after living donor liver transplantation in patients with biliary atresia: a relatively high incidence of portal vein complications
Q44230295Tacrolimus in pediatric liver transplantation
Q28258318Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation
Q73578526Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation
Q89036819The Impact of Preoperative Hemoglobin Level on the Short-Term Outcomes After Living Donor Liver Transplantation
Q74686089The necessity for steroid induction or long-term maintenance after liver transplantation: the argument against
Q77736673Treatment of ornithine transcarbamylase deficiency in girls by auxiliary liver transplantation: conceptual changes in a living-donor program

Search more.